Stocks To Buy Now

Blog


Zauben Pitches their Innovative & Sustainable Product at the 5th Annual Sustainability Private Capital Event

Zauben, known for its Model Z living wall concept, attended the 5th Annual Sustainability Private Capital Event on December 7-8, 2022. The event was jointly hosted by Sustain SoCal and Roth Capital Partners. Venture capitalists and investors from private equity, family offices, endowments, foundations and angels attended the conference. This two-day virtual event offered a mammoth networking and business opportunity to connect with C-level executives with established private sustainability companies, mostly series A/B, in the solar/storage, e-mobility, Smart City, circular economy and water verticals Winner of several prestigious awards for sustainability and innovation, Zuben’s premier product, Model Z living wall, allows businesses, organizations, and anyone to bring the beauty and benefits of outdoor greenery indoors, without worrying about maintenance. Their system incorporates hydroponic technology that uses 75% less water than plants grown in soil. It is fitted with a 1-month water tank that recirculates water, hence no plumbing or drainage is needed. The hydroponic recyclable growth medium is 10x more efficient than soil, minimizing the risk of dirt and bugs. Even the plant light setting is contoured to earth’s natural light cycle, reducing energy consumption while keeping the indoor atmosphere pleasant. In addition, Zauben monitors the living wall in real-time to ensure that it functions efficiently. The team at Zauben works to impact climate change by employing a recyclable hydroponic growth medium that is energy efficient. To learn more about the conference, please visit https://ibn.fm/0AUAF https://ibn.fm/YBuOk. To learn more about Zauben, please visit (https://www.zauben.com/).

From Our Blog

Soligenix Inc. (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

April 17, 2026

Recognition from global regulatory authorities can serve as a powerful validation of a therapy’s potential, particularly in the rare disease space where development challenges are significant and patient needs are urgent. Soligenix (NASDAQ: SNGX) has secured that type of validation, as the European Commission granted orphan drug designation to its investigational therapy SGX945 for the […]

Rotate your device 90° to view site.